Evaluating the therapeutic effects of NiaoDuQing particles on chronic kidney disease based on real world study.

IF 1.4 4区医学 Q4 ENGINEERING, BIOMEDICAL Technology and Health Care Pub Date : 2024-07-28 DOI:10.3233/THC-241029

Rui Sun, Jianfeng Hao, Qian Li, Weinan Xie, Xiaoyan Hu, Zhenzhen Chen, Zhi Liu, Ling Yuan

{"title":"Evaluating the therapeutic effects of NiaoDuQing particles on chronic kidney disease based on real world study.","authors":"Rui Sun, Jianfeng Hao, Qian Li, Weinan Xie, Xiaoyan Hu, Zhenzhen Chen, Zhi Liu, Ling Yuan","doi":"10.3233/THC-241029","DOIUrl":null,"url":null,"abstract":"Background: NiaoDuQing Particle is the first Chinese herbal medicine approved by the China Food and Drug Administration for the treatment of chronic kidney disease. It has been used in clinical practice in China for over twenty years. However, there is limited literature reporting on the long-term therapeutic effects of NiaoDuQing Particles on chronic kidney disease patients.Objective: This research aimed to comprehensively assess the therapeutic effect of NiaoDuQing Particles (NDQP) on chronic kidney disease patients based on clinical data analysis.Methods: This study was carried out on a total of 148 participants diagnosed with different types of chronic kidney disease. Demographics information, chronic kidney disease classification and chronic kidney disease diganostic indicators were collected and analyzed before and after NiaoDuQing Particles treatment for 3, 6, 9, 12 and 18 months respectively.Results: In all 148 patients, mean eGFR value was increased after NiaoDuQing Particles treatment for up to 18 months, and was statistically significant at month 3, 6, 9, 12 and 18 (P< 0.05). Mean uric acid value was decreased after NiaoDuQing Particles treatment for up to 18 months, and was statistically significant at month 3, 6, 9, 12 and 18 (P< 0.05). Mean urea nitrogen value was decreased after NiaoDuQing Particles treatment for up to 18 months and was statistically significant at month 3, 6, 9, 12 and 18 (P< 0.05). While mean creatinine value was decreased after NiaoDuQing Particles treatment for up to 18 months and was statistically significant at month 6 (P< 0.05).Conclusions: NiaoDuQing Particles could maintain the stable state of chronic kidney disease patients for up to 18 months especially in improving diagnostic indicators like eGFR, uric acid and urea nitrogen.","PeriodicalId":48978,"journal":{"name":"Technology and Health Care","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2024-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Technology and Health Care","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.3233/THC-241029","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: NiaoDuQing Particle is the first Chinese herbal medicine approved by the China Food and Drug Administration for the treatment of chronic kidney disease. It has been used in clinical practice in China for over twenty years. However, there is limited literature reporting on the long-term therapeutic effects of NiaoDuQing Particles on chronic kidney disease patients.

Objective: This research aimed to comprehensively assess the therapeutic effect of NiaoDuQing Particles (NDQP) on chronic kidney disease patients based on clinical data analysis.

Methods: This study was carried out on a total of 148 participants diagnosed with different types of chronic kidney disease. Demographics information, chronic kidney disease classification and chronic kidney disease diganostic indicators were collected and analyzed before and after NiaoDuQing Particles treatment for 3, 6, 9, 12 and 18 months respectively.

Results: In all 148 patients, mean eGFR value was increased after NiaoDuQing Particles treatment for up to 18 months, and was statistically significant at month 3, 6, 9, 12 and 18 (P< 0.05). Mean uric acid value was decreased after NiaoDuQing Particles treatment for up to 18 months, and was statistically significant at month 3, 6, 9, 12 and 18 (P< 0.05). Mean urea nitrogen value was decreased after NiaoDuQing Particles treatment for up to 18 months and was statistically significant at month 3, 6, 9, 12 and 18 (P< 0.05). While mean creatinine value was decreased after NiaoDuQing Particles treatment for up to 18 months and was statistically significant at month 6 (P< 0.05).

Conclusions: NiaoDuQing Particles could maintain the stable state of chronic kidney disease patients for up to 18 months especially in improving diagnostic indicators like eGFR, uric acid and urea nitrogen.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

基于真实世界的研究，评估牛膝颗粒对慢性肾病的治疗效果。

背景：牛膝颗粒是中国食品药品监督管理局批准用于治疗慢性肾病的第一种中药。它在中国的临床实践中已使用了二十多年。然而，有关牛膝颗粒对慢性肾病患者长期治疗效果的文献报道却很有限：本研究旨在通过临床数据分析，全面评估 "牛膝颗粒 "对慢性肾脏病患者的治疗效果：研究对象为148名不同类型的慢性肾脏病患者。所有148名患者在 "牛膝颗粒 "治疗18个月后的平均eGFR值均有所上升，且在第3、6、9、12和18个月时均有统计学意义（P< 0.05）。尿酸平均值在服用 "蚕豆清颗粒 "18 个月后有所下降，在第 3、6、9、12 和 18 个月时有统计学意义（P< 0.05）。尿素氮的平均值在服用 "牛膝颗粒 "18 个月后有所下降，并在第 3、6、9、12 和 18 个月时有统计学意义（P< 0.05）。结论：蚕豆清颗粒治疗18个月后，平均肌酐值下降，在第6个月时有统计学意义（P< 0.05）：结论："牛膝颗粒 "可维持慢性肾脏病患者的稳定状态长达18个月，尤其是在改善eGFR、尿酸和尿素氮等诊断指标方面。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Technology and Health Care HEALTH CARE SCIENCES & SERVICES-ENGINEERING, BIOMEDICAL

CiteScore

2.10

自引率

6.20%

发文量

282

审稿时长

>12 weeks

期刊介绍： Technology and Health Care is intended to serve as a forum for the presentation of original articles and technical notes, observing rigorous scientific standards. Furthermore, upon invitation, reviews, tutorials, discussion papers and minisymposia are featured. The main focus of THC is related to the overlapping areas of engineering and medicine. The following types of contributions are considered: 1.Original articles: New concepts, procedures and devices associated with the use of technology in medical research and clinical practice are presented to a readership with a widespread background in engineering and/or medicine. In particular, the clinical benefit deriving from the application of engineering methods and devices in clinical medicine should be demonstrated. Typically, full length original contributions have a length of 4000 words, thereby taking duly into account figures and tables. 2.Technical Notes and Short Communications: Technical Notes relate to novel technical developments with relevance for clinical medicine. In Short Communications, clinical applications are shortly described. 3.Both Technical Notes and Short Communications typically have a length of 1500 words. Reviews and Tutorials (upon invitation only): Tutorial and educational articles for persons with a primarily medical background on principles of engineering with particular significance for biomedical applications and vice versa are presented. The Editorial Board is responsible for the selection of topics. 4.Minisymposia (upon invitation only): Under the leadership of a Special Editor, controversial or important issues relating to health care are highlighted and discussed by various authors. 5.Letters to the Editors: Discussions or short statements (not indexed).